Challenge:  SCYNEXIS was launching Brexafemme, a pill treatment for oral treatment designed to eliminate the yeast causing infection in September 2021. Brexafemme is The first modern prescription oral treatment the market. They had not IT strategy and limited Systems and no support IT for a Commercial launch Solution:  Implem...

Challenge:  Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for rare diseases. They also needed to be preparing for Fruquintinib in 2023. They had no IT strategy nor any Systems in place to enable and support the launch. The commercialization would ...